PHARMACOLOGICAL TREATMENT OF PARKINSON’S DISEASE: MOLECULAR ASPECTS AND PROSPECTS

DOI: https://doi.org/10.29296/24999490-2018-02-01

M.A. Paltsev(1), V.A. Zuev(2), A.S. Diatlova(2, 3), N.S. Linkova(2, 3), T.V. Kvetnaia(2) 1-Academic Research Center of the Financial Universi ty, Leningradsky Prospekt, 49, Moscow, 125993, Russian Federation; 2-Saint Petersburg Institute of Bioregulation and Gerontology, Dynamo pr., 3, Saint Petersburg, 197110, Russian Federation; 3-Peter the Great Saint Petersburg Polytechnic University, Polytechnicheskaya str. 29, Saint Petersburg, 195251, Russian Federation E-mail: [email protected]

Parkinson’s disease (PD) is a progressive, age-related, neuronal disorder that affects as much as 1% of the persons over 65 years. According to forecasts of the World Health Organization over the world about 9 million people will suffer from PD by 2030. So PD is an actual medical and social problem. Pharmacotherapy of PD is directed to the treatment of symptoms and includes dopaminergic therapy, generally. Dopaminergic therapy presents the wide group of preparations, such as levodopa, dopamine receptor agonists and monoaminoxidase inhibitors. These preparations are not selective and have a wide spectrum of side effects under conditions of the long-term use. Innovation approaches for PD treatment are directed not only to the elimination of symptoms, but also to the correction of various pathogenesis elements of PD. There are two innovation approaches for PD treatment: gene therapy and antioxidant therapy for the prevention the mitochondrial dysfunction. Further investigations in the field of gene and antioxidant therapy will allow develop more selective drugs that have less side effects and will be more effective than those already used.
Keywords: 
Parkinson’s disease, dopaminergic therapy, gene therapy, antioxidant therapy
Список литературы: 
  1. laboratornye biomarkery ranney diagnostiki bolezni Parkinsona. Mezhdunarodnyy nevrologicheskiy zhurnal. 2016; 3 (81): 17–22. [Ponomarev V.V., Bojko A.V., Ionova O.A. Laboratory biomarkers of early diagnostics of Parkinson’s disease. International neurology journal. 2016; 3 (81): 17–22 (in Russian)]
  2. Fahn S. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism and Related Disorders. 2017; 1-5.
  3. Geht A.B., Popov G.R. Medicinskie i social`nye aspekty bolezni Parkinsona. Bolezn` Parkinsona i rasstroystva dvizheniya. M.: ZAO «RKI Sovero press», 2014; 450. [Geht A.B., Popov G.R. Medical and Social aspects of Parkinson’s disease. Parkinson’s disease and moving disorder. M.: «RKI Sovero Press», 2014; 450 (in Russian)]
  4. Campenhausen S., Bornschein B. Prevalence and incidence of Parkinson’s disease in Europe. European Neuropsychopharmacology. 2005; 15: 473–90.
  5. Casetta I., Granieri E., Govoni V., Tola M.R., Paolino E., Monetti V.C., Caniatti L. Epidemiology of Parkinson’s disease in Italy. A descriptive survey in the U.S.L. of Cento, province of Ferrara, Emilia-Romagna. Acta Neurol (Napoli). 1990; 8: 284.
  6. Cacabelos R. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int J. Mol. Sci. 2017; 18 (3). pii: E551. doi: 10.3390/ijms18030551.
  7. Levin O.S., Tumgoeva A.I., Batukaeva L.A. Problema priverzhennosti terapii bol`nyh pri bolezni Parkinsona. Sovremennaya terapiya v psihiatrii i nevrologii. 2016; 4: 9–13. [Levin O.S., Tumgoeva A.I., Batukaeva L.A. Problems of theragy adherence in Parkinson’s disease. Modern therapy and psychiatry and neurology. 2016; 4: 9–13 (in Russian)]
  8. Gusev E.I., Konovalov A.N., Burd G.S. Nevrologiya i neyrohirurgiya. M.: Medicina, 2004; 374. [Gusev E.I., Konovalov A.N., Burd G.S. Nevrology and neurosurgery. M.: Medicine, 2004; 374 (in Russian)]
  9. Gusev E.I., Konovalov A.N., Skvorcova V.I., Geht A.B. Nevrologiya. Nacional`noe rukovodstvo. M.: GE`OTAR-Media, 2009; 2116. [Gusev E.I., Konovalov A.N., Skvortsova V.I., Geht A.B. Neurology. National guidance. M.: GEOTAR-Media, 2009; 2116 (in Russian)]
  10. Illarioshkin S.N. Sovremennye predstavleniya ob e`tiologii bolezni Parkinsona. Nevrologicheskiy zhurnal. 2015; 20 (4): 4–13. [Illarioshkin S.N. Modern aspects of Parkinson’s disease etiology. Neurology journal. 2015; 20 (4): 4–13 (in Russian)]
  11. Kucak A.V., Buchakchiyskaya N.M. Sovremennye vzglyady na voprosy e`tiologii i patogeneza bolezni Parkinsona. Zaporozhskiy medicinskiy zhurnal. 2016; 6 (99): 88–92. [Kytsac A.V., Buchakchijckaya N.M. Modern views and questions of etiology and pathogenesis of Parkinson’s disease. Zaporoshskij medical journal. 2016; 6 (99): 88–92 (in Russian)]
  12. Dick F.D., De Palma G., Ahmadi A., Scott N.W., Prescott G.J., Bennett J., Semple S., Dick S., Counsell C., Mozzoni P., Haites N., Wettinger S.B., Mutti A., Otelea M., Seaton A., Söderkvist P., Felice A. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup. Environ. Med. 2007; 64: 666–72.
  13. Gatto N.M., Cockburn M., Bronstein J., Manthripragada A.D., Ritz B. Well-water consumption and Parkinson’s disease in rural. California. Environ. Hlth Perspect. 2009; 11: 1912–8.
  14. Shtul`man D.R. Bolezni nervnoy sistemy. M.: Medicina, 2001; 744. [Shtulman D.R. Diseases of nervous system. M.: Medicine, 2001; 744 (in Russian)]
  15. Dubinina E.E., Pustygina A.V. Svobodnoradikal`nye processy pri starenii, neyrodegenerativnyh zabolevaniyah i drugih patologicheskih sostoyaniyah. Biomedicinskaya himiya. 2007; 53 (4): 351–72. [Dubinina E.E., Pustigina A.V. Free radical processes in ageing, neurodegenerative diseases and other pathology. Biomedical Chemistry. 2007; 53 (4): 351–72].
  16. Pchelina S.N. Al`fa-sinuklein kak marker bolezni Parknsona. Annaly klinicheskoy i e`ksperimental`noy nevrologii. 2011; 5 (4): 46–51. [Pchelina S.N. Alpha –synuclein as a marker of Parkinson’s disease. Annals of clinical and experimental neurology. 2011; 5 (4): 46–51 (in Russian)]
  17. Bublikova A.M., Statinova E.A., Kocenko Yu.I., Sohina V.S. E`tiologiya i patogenez bolezni Parkinsona – vzglyad na problemu segodnya. Universitetskaya klinika. 2016; 12 (2): 67–9. [Bublikova A.M., Ststinova E.A., Kotsenko Yu.I., Sochina V.S. Etiology and pathogenesis of Parkinson’s disease – the view to the problem now. University Clinic. 2016; 12 (2): 67–9 (in Russian)]
  18. Golubev V.L. Lechenie bolezni Parkinsona: reshennye i nereshennye voprosy. V kn.: Izbrannye lekcii po nevrologii. M.: E`ydos Media, 2006; 420. [Golubev V.L. Treatment of Parkinson’s disease: solve and non-solve questions. In book «Choose lections in nevrology». M.: Eikos Media, 2006; 420 (in Russian)]
  19. Illarioshkin S.N. Terapiya parkinsonizma: vozmozhnosti i perspektivy. Consilium Medicum. 2009; 1: 35–40. [Illarioshkin S.N. Parkinsonism therapy: ability and perspectives. Consilium Medicum. 2009; 1: 35–40 (in Russian)]
  20. Ko J.H., Lerner R.P., Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord. 2015; 30 (1): 54–63.
  21. Katunina E.A., Bezdol`nyy Yu.N., Malyhina E.A., Titova N.V. Opyt primeneniya levodopy-benserazida. Nevrologiya, neyropsihiatriya, psihosomatika. 2015; 3: 93–7. [Katunina E.A., Bezdolnij Yu. N., Malichina E.A., Titova N.V. The experience of using levodopa-benserazid. Neurology, neuropsychiatry, psichosomatiss. 2015; 3: 93–7 (in Russian)]
  22. Fedorova N.V., Yablonskaya A.Yu., Bel`gusheva M.E`. Preparaty levodopy v lechenii bolezni Parkinsona. Zhurnal nevrologii i psihiatrii. 2011; 5: 30–6. [Fedorova N.V., Yablonskaya A.Yu., Belgusheva M.E. Levodopa drugs in Parkinson’s disease treatment. J. of neurology and psychiatry. 2011; 5: 30–6 (in Russian)]
  23. Timofeeva A.A. Lechenie pozdnih stadiy bolezni Parkinsona: e`ffektivnost` i bezopasnost` levodopa/karbidopa intestinal`nogo gelya. Zhurnal nevrologii i psihiatrii. 2014; 11: 145–51. [Timofeeva A.A. Treatment of Parkinson’s disease late studies: efficiency and safety levodopa/carbidopa intestinal gel. J. of neurology and psychiatry. 2014; 11: 145–51 (in Russian)]
  24. Levin O.S., Artem`ev D.V., Bril` E.V., Kulua T.K. Bolezn` Parkinsona: sovremennye podhody k diagnostike i lecheniyu. Prediktivnaya medicina. 2017; 1 (102): 45–51. [Levin O.S., Armeriev D.V., Bril E.V., Kulua T.K. Parkinson’s disease: modern ways to diagnostic and treatment. Predictive medicine. 2017; 1 (102): 45–51 (in Russian)]
  25. Alam M., Schmidt W.J. l-DOPA reverses the hypokinetic behavior and rigidity in rotenone-treated rats. Behav. Brain Res. 2004; 153: 439–46.
  26. Levin O.S. Levodopa-inducirovannye diskinezii pri bolezni Parkinsona: vozmozhnosti preduprezhdeniya i terapii. Sovremennaya terapiya v psihiatrii i nevrologii. 2015; 3: 15–25. [Levin O.S. Levodopa-indiced diskinesy during Parkinson’s disease: preventive ability and therapy. Modern therapy and psychiatry and neurology. 2015; 3: 15–25 (in Russian)]
  27. Pilipovich A.A., Golubev V.L. Amantadiny: opyt primeneniya pri bolezni Parkinsona. Medicinskiy sovet. 2016; 11: 52–6. [Pilipovich A.A., Golubev V.L. Amantadins: the experience of using during Parkinson’s disease. Medical advice. 2016; 11: 52–6 (in Russian)]
  28. Elahi B., Phielipp N., Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J. Neurol Sci. 2012; 39: 465–72.
  29. Chung J.S., Wu A.D., Lew M.F. Amantadine and Anticholinergics. Handbook of Parkinson’s Disease, Fifth Edition. CRC Press. 2013; 619.
  30. Illarioshkin S.N. Proizvodnye amantadina v lechenii bolezni Parkinsona. Nervnye bolezni. 2016; 3: 14–8. [Illarioshkin S.N. Amantadin derivates in Parkinson’s disease treatment. Neurology diseases. 2016; 3: 14–8 (in Russian)]
  31. Van Camp G., Flamez A., Cosyns V., Weytjens C., Muyldermans L., Van Zandijcke M., De Sutter J., Santens P., Decoodt P., Moerman C., Schoors D. Treatment of Parkinson’s disease with ergolide and relation to restrictive valvular heart disease. Lancet. 2004; 363: 1179–83.
  32. Titova N.V. Sovremennyy vzglyad na angonisty dofaminovyh receptorov v terapii bolezni Parkinsona. Zhurnal nevrologii i psihiatrii. 2015; 9: 76–83. [Titova N.V. Novel view on antagonists of dopamine receptors in Parkinson’s disease therapy. J. of neurology and psychiatry. 2015; 9: 76–83 (in Russian)]
  33. Katunina E.A., Titova N.V., Bezdol`nyy Yu.N., Shikkerimov R.K., Gasanov M.G., Burd S.G. Agonisty dofaminovyh receptorov: novye formy i novye vozmozhnosti v lechenii bolezni Parkinsona. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015; 5: 34–40. [Katunina E.A., Titova N.V., Bezdolnij Yu.N., Shikkerimov R.K., Gasanov M.G., Burd S.G. Dopamine receptors agonists: new forms and new ability in Parkinson’s disease treatment. J. of neurology and psychiatry named after S.S. Korsakov. 2015; 5: 34–40 (in Russian)]
  34. Picillo M., Rocco M., Barone P. Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2009; 15 (4): 1–84. doi: 10.1016/S1353-8020(09)70841-7.
  35. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., Poewe W., Rascol O., Goetz C.G., Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011; 26 (3): 2–41.
  36. Mizuno Y., Hattori N., Kondo T., Nomoto M., Origasa H., Takahashi R., Yamamoto M., Yanagisawa N. A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease. Clin. Neuropharmacol. 2017; 40 (5): 201–7.
  37. Murakami H., Nohara T., Uchiyama M., Owan Y., Futamura A., Shiromaru A., Tsukada S., Saito Y., Kuroda T., Yano S., Ishigaki S., Katoh H., Munechika J., Ohgiya Y., Gokan T., Ono K. Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naive Parkinson’s Disease. Front Aging Neurosci. 2017; 9: 321. doi: 10.3389/fnagi.2017.00321.
  38. Oldfield V., Keating G.M., Perry C.M. Rasagiline: a review of its use in the management of Parkinson’s disease. Drugs. 2007; 67 (12): 1725–47.
  39. Illarioshkin S.N. Novyy ingibitor MAO-B razagilin – preparat dlya patogeneticheskogo i simptomaticheskogo lecheniya bolezni Parkinsona. Nervnye bolezni. 2008; 3: 7–12. [Illarioshkin S.N. New inhibitor MAO-B rasalgin – drug for pathogenesis and symptomatic treatment of Parkinson’s disease. Neuropathology. 2008; 3: 7–12 (in Russian)]
  40. Cereda E., Cilia R., Canesi M., Tesei S., Mariani C.B., Zecchinelli A.L., Pezzoli G. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J. Neurol. 2017; 264 (6): 1254–63.
  41. Yurkevich M.Yu., Zafranskaya M.M., Ponomarev V.V., Boyko A.V., Aleynikova N.E. Kletochnaya terapiya bolezni Parkinsona: dostizheniya i perspektivy. Mezhdunarodnyy nevrologicheskiy zhurnal. 2017; 4 (90): 93–101. [Yurkevich M.Yu., Zafranskaya M.M., Ponomarev V.V., Boiko A.V., Alejnikova N.E. Cell therapy of Parkinson’s disease: attainments and perspectives. International neurology J. 2017; 4 (90): 93–101 (in Russian)]
  42. Boroujeni M.E., Gardaneh M. Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons. Neural Regen Res. 2017; 7: 1186–92.
  43. Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. Prog Brain Res. 2017; 230: 213–26.
  44. Kovalenko V.R., Habarova E.A., Rzaev D.A., Medvedev S.P. Kletochnye modeli, genomnye tehnologii i klinicheskaya praktika: sintez znaniy dlya issledovaniya mehanizmov, diagnostiki i terapii bolezni Parkinsona. Geny i kletki. 2017; 2: 11–28. [Kovalenko V.R., Khabarova E.A., Rzaev D.A., Medvedev S.P. Cell models, genomes technology and clinical practice: knowledge synthesis for mechanisms, diagnostic and therapy investigations of Parkinson’s disease. Genes and cells. 2017; 2: 11–28 (in Russian)]
  45. Zhou X., Xin J., Fan N., Zou Q., Huang J., Ouyang Z., Zhao Y., Zhao B., Liu Z., Lai S., Yi X., Guo L., Esteban M.A., Zeng Y., Yang H., Lai L. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell. Mol. Life Sci. 2015; 72 (6): 1175–84.
  46. Wang X., Cao C., Huang J., Yao J., Hai T., Zheng Q., Wang X., Zhang H., Qin G., Cheng J., Wang Y., Yuan Z., Zhou Q., Wang H., Zhao J. One-step generation of triple gene- targeted pigs using CRISPR/Cas9 system. Sci. Rep. 2016; 9 (6): 1–7.
  47. Liu Y.Y., Yang X.Y., Li Z., Liu Z.L., Cheng D., Wang Y., Wen X.J., Hu J.Y., Liu J., Wang L.M., Wang H.J. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson’s disease. CNS Neurosci Ther. 2014; 20 (1): 76–85.
  48. Maiti P., Manna J., Dunbar G.L. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Transl Neurodegener. 2017; 6 (28): doi: 10.1186/s40035-017-0099-z.
  49. Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., Kaplan P.L., Forsayeth J., Aminoff M.J., Bankiewicz K.S. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum Gene Ther. 2012; 4: 377–81.
  50. Kim-Ha J., Kim Y.J. Age-related epigenetic regulation in the brain and its role in neuronal diseases. BMB Rep. 2016; 49 (12): 671–80.
  51. Desplats P., Spencer B., Coffee E., Patel P., Michael S., Patrick C., Adame A., Rockenstein E., Masliah E. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J. Biol. Chem. 2011; 286 (11): 9031–7.
  52. Lungu G., Stoica G., Ambrus A. MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model. Neurosci Lett. 2013; 553: 153–8.
  53. Roy A., Ghosh A., Jana A., Liu X., Brahmachari S., Gendelman H.E., Pahan K. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLoS One. 2012; 7 (6). e38113. doi: 10.1371/journal.pone.0038113.
  54. Muroyama A., Fujita A., Lv C., Kobayashi S., Fukuyama Y., Mitsumoto Y. Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson’s Disease. Parkinsons Dis. 2012. doi: 10.1155/2012/985157.
  55. Singh S., Jamwal S., Kumar P. Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Neural Regen Res. 2017; 7: 1137–44.
  56. López A., Ortiz F., Doerrier C. Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases. PLoS One. 2017; 12 (8). e0183090. doi: 10.1371/journal.pone.0183090.
  57. Samoylenko V., Rahman M.M., Tekwani B.L., Tripathi L.M., Wang Y.H., Khan S.I., Khan I.A., Miller L.S., Joshi V.C., Muhammad I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol. 2010; 127 (2): 357–67.
  58. Romuk E., Szczurek W., Nowak P., Skowron M., Prudel B., Hudziec E., Chwalińska E., Birkner E. Effects of Propofol on Oxidative Stress Parameters in Selected Parts of the Brain in a Rat Model of Parkinson Disease. Postepy Hig Med Dosw. 2016; 70: 1441–50.